Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

The switch that promotes kidney cancer progression and metastasis

December 12, 2014 – 2:54 pm | Edit Post

How kidney cancer becomes metastatic

Key Economic Drivers to Keep Fueling Real Estate Demand

December 12, 2014 – 11:54 am | Edit Post

Technology, biotech, defense and tourism – and various combinations of all four – are expected to have a continued strong impact on local real estate demand in 2015 and beyond, said experts at a recent symposium on the subject.

Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting

December 12, 2014 – 6:00 am | Edit Post

SAN DIEGO, Dec. 12, 2014 /PRNewswire/ – Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) today. The first of the presentations includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes additional supportive preclinical information on the utility of hyaluronan (HA) as a potential biomarker for cancer treatments. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme. PEGPH20 degrades the hyaluronan coating that may provide a supportive environment in many solid tumors.

SABCS Poster Presentation Details

Title: “Hyaluronan Depletion Sensitizes HAhigh Tumors to Antibody-Dependent Cell-Mediated Cytotoxicity”Poster Session: P5-04-02, December 12, 2014, 7:00AM – 7:00PM CDTLocation: Exhibit Hall A-BSummary: About 50% of HER2+3 breast cancers and 12% of ovarian cancers accumulate abundant HA in the tumor microenvironment. The accumulation of HA is known to result in decreased access of therapeutics to the tumor.  Therefore, HA accumulation may contribute to trastuzumab resistance. When HA is depleted by treatment with PEGPH20 in vitro, HAhigh/HER2+3 cells become much more sensitive to antibody-mediated cellular cytotoxicity. Additionally, HAhigh/HER2+3 human tumors in mice treated with PEGPH20 increased the access of trastuzumab and immune cells to the tumor, resulting in enhanced antitumor activity. These results suggest that co-administration of PEGPH20 could enhance the efficacy of trastuzumab in HAhigh/HER2+3 tumors.

Title: “Naked Mole Rat HAS2 and Hyaluronan Are Not Tumor Suppressive in Human Tumor Xenografts”Poster Session: P4-04-25, December 12, 2014, 7:00AM – 7:00PM CDTLocation: Exhibit Hall A-BSummary:  Published third-party literature suggests that naked mole rat hyaluronan synthase 2 (nmrHAS2) produces extraordinarily high molecular weight HA, which has tumor suppressive effects. Transfection of the nmrHAS2 gene into human tumor cells did not suppress the growth of human tumors in nude mice and suggests that HA in the naked mole rat may have different functions than in human cancer, where HA accumulation promotes tumor growth.

About HalozymeHalozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the company’s research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme’s pipeline addresses therapeutic areas, including oncology, diabetes and dermatology that have significant unmet medical need today. The company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer and Baxter. Halozyme is headquartered in San Diego. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the possible activity, benefits and attributes of PEGPH20, the possible method of action of PEGPH20, its potential application to improve cancer therapies and statements concerning future actions relating to the development of PEGPH20) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2014.

Investor Contact:Schond GreenwayHalozyme Therapeutics858-704-8352ir@halozyme.com

Media Contact:Susan Neath Francis212-301-7182sfrancis@wcgworld.com

Logo - http://photos.prnewswire.com/prnh/20100302/LA63139LOGO

 

SOURCE Halozyme Therapeutics, Inc.

Isis Pharma shares hit all-time high

December 11, 2014 – 5:54 pm | Edit Post

Shares of the Carlsbad biotech reached $65.13 intraday, closed at $61.87

Obese Children’s Brains More Responsive To Sugar, University of California, San Diego (UCSD) Study

December 11, 2014 – 5:00 pm | Edit Post

Obese Children’s Brains More Responsive To Sugar A new study led by researchers at University of California, San Diego School of Medicine finds that the brains of obese children literally light up differently when tasting sugar.Published online in International Journal of Obesity, the study does not show a causal relationship between sugar hypersensitivity…

MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) Announces Pricing Of Public Offering Of Common Stock

December 11, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 12, 2014 /PRNewswire/ –MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has priced an underwritten public offering of 10,000,000 shares of its common stock at an offering price of

Halozyme Therapeutics, Inc. Announces Presentations Of Preclinical Data At The

December 11, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 12, 2014 /PRNewswire/ –Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) today. The first of the presentations includes preclinical…

Obese Kids’ Brains Crave For Sugar, University of California, San Diego (UCSD) Study

December 11, 2014 – 5:00 pm | Edit Post

Obese Children’s Brains More Responsive To Sugar A new study led by researchers at University of California, San Diego School of Medicine finds that the brains of obese children literally light up differently when tasting sugar.Published online in International Journal of Obesity, the study does not show a causal relationship between sugar hypersensitivity…

Batu Biologics Submits Investigational New Drug Application For Lung Cancer Anti-Angiogenic Immunotherapy With FDA

December 11, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Batu Biologics, a biotechnology company focusing on developing therapies that target the Achilles Heel of Cancer: the tumor blood vessels, announced today the filing of an Investigational Drug Application (IND) with the U.S. Food and Drug Administration (FDA) for its lead immune therapy, ValloVax. Once the IND is approved, Batu Biologics will proceed with a Phase I/II clinical…

Batu Biologics Submits Investigational New Drug Application For Lung Cancer Anti-Angiogenic Immunotherapy With FDA

December 11, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Batu Biologics, a biotechnology company focusing on developing therapies that target the Achilles Heel of Cancer: the tumor blood vessels, announced today the filing of an Investigational Drug Application (IND) with the U.S. Food and Drug Administration (FDA) for its lead immune therapy, ValloVax. Once the IND is approved, Batu Biologics will proceed with a Phase I/II clinical…